運用清冠一號於COVID-19病例報告

Taiwan Chingguan Yihau (NRICM101) for Severe COVID-19 Pneumonia: A Case Report

10.6516/TJTCM.202203/SP_25.0016

沈欣儀(Hsin-Yi Shen)；柯君頤(Chun-Yi Ke)；陳星諭(Hsing-Yu Chen)；陳俊良(Jiun-Liang Chen)

新冠肺炎 ； 新冠肺炎重症 ； 清冠一號 ； 病例報告 ； COVID-19 pneumonia ； Severe COVID-19 infection ； Taiwan Chingguan Yihau (NRICM101) ； Case report

中醫藥研究論叢

25卷特刊（2022 / 03 / 05）

137 - 147

繁體中文

新冠肺炎於2019年底爆發，並因其極高的傳染力快速席捲全球，台灣亦於今年五月起經歷一波大規模的本土感染。快速增加的確診個案迫使醫師必須盡快分辨危急及輕症病患，以確保醫療資源能達最大效率使用。另在高度傳染性疾病的威脅下，傳統中醫望聞問切四診合參的診治模式受到限制，在疫情下如何參與疾病防治為當前主要議題。本病案為一68歲有多重慢性疾病之男性，因發燒、呼吸困難至急診求助，經篩檢後確診為新冠肺炎患者，並因慢性疾病及初起一般空氣下氧氣飽和度93%被歸類為重症病患，初始藥物包括類固醇、Interleukin-6 Inhibitors（IL-6 inhibitor）、抗生素及Remdesivir，並於入住加護病房時接受清冠一號合併治療。患者於住院隔日即退燒，十日內症狀緩解而出院返家隔離。藉由此病案我們將討論清冠一號在此類患者之適用性。

The COVID-19 pneumonia broke out at the end of 2019 and rapidly swept the world due to its extremely high infectivity. Taiwan also suffered from COVID-19 epidemic since this May. The epidemic forced the physicians to identify severe, moderate, and mild patients as soon as possible to ensure that medical resources can be used with maximum efficiency. In addition, we should think about the ways to participate in disease control under the threat of highly contagious diseases with inappropriate traditional Chinese medicine diagnosis model of Wang, Wen, Wen, Qi. This case was a 68-year-old man with multiple chronic diseases. He went to the emergency room for fever and dyspnea. After screening, he was diagnosed as COVID-19 pneumonia. He was classified as a severe case since his had chronic diseases and the initial oxygen saturation in the room air was 93%. The treatment of severe cases included steroids, Interleukin-6 Inhibitors (IL-6 inhibitor), antibiotics and Remdesivir, and the patient received combined treatment with Taiwan Chingguan Yihau (NRICM101) when admitted to the intensive care unit. Fever subsided the next day after being hospitalized, and the symptoms were all improved within 10 days. With this case, we will discuss the applicability of NRICM101 in COVID-19 pneumonia patients.

1. Abrahim, SA,Tessema, M,Defar, A(2021).Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia.PLOS ONE,15(12),e0244269.
2. Barman, MP,Rahman, T,Bora, K,Borgohain, C(2020).COVID-19 pandemic and its recovery time of patients in India: A pilot study.Diabetes & Metabolic Syndrome: Clinical Research & Reviews,14(5),1205-1211.
3. Gandhi, RT,Lynch, JB,del Rio, C(2020).Mild or Moderate Covid-19.New England Journal of Medicine,383(18),1757-1766.
4. Health NIo(2021).Health NIo. COVID-19 Treatment Guidelines. 2021..
5. Oran, DP,Topol, EJ(2021).The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review.Ann Intern Med,174(5),655-662.
6. Organization WH(2021).Organization WH. Weekly Operational Update on COVID-19. 2021..
7. Organization WH(2021).Organization WH. Therapeutics and COVID-19: living guideline. 2021..
8. Tsai, K-C,Huang, Y-C,Liaw, C-C(2021).A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.Biomedicine & Pharmacotherapy,133,111037.
9. 張德新(2009)。荊防敗毒散臨床應用體會。陝西中醫，10，1404-1405。
10. 許喬波,馬戰平,李猛,薛敬東,劉莉君(2020)。馬戰平主任醫師基於“冬不藏精，春必病溫＂理論探析新型冠狀病毒肺炎發病機制。陝西中醫，41(7)，843-845。
11. 楊冠男,薑欣,穀曉紅(2020)。從中醫膜系理論探討新型冠狀病毒肺炎的防治策略。Journal of Beijing University of Traditional Chinese Medicine，43(8)
12. 劉耀崠,楊逸淦,柯麗萍(2018)。“溫邪上受，首先犯肺，逆傳心包＂之辨析。中國中醫基礎醫學雜誌，24(2)，155-156。
13. 衛生福利部(2021)。衛生福利部：嚴重特殊傳染性肺炎確診個案處置及解除隔離治療條件 .pdf。2021。
14. 衛生福利部國家中醫藥研究所：新型冠狀病毒病中醫臨床分期治療指引。June 1, 2020 2020. https://www.nricm.edu.tw/p/406-1000-6141,r11.php?Lang=zh-tw (accessed Sep 17, 2021 2021).
15. 衛生福利部國家中醫藥研究所：臺灣清冠一號（NRICM101）處方依據、方解和基礎研究。May 16, 2021 2021. https://www.nricm.edu.tw/p/406-1000-6497,r61.php?Lang=zh-tw (accessed Sep 17 2021).
16. 謝穎楨,高穎,鄒憶懷(2001)。試論毒邪致病及證候特徵。北京中醫藥大學學報，24(1)，11-13。